Company Biopharmx Corp Nyse

Timber Pharmaceuticals, Inc., formerly BioPharmX Corporation, is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for orphan dermatologic diseases. It is developing treatments for rare dermatologic diseases including congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and localized scleroderma. Its pipeline includes TMB-001, TMB-002 and TMB-003. TMB-001 is a topical isotretinoin, which is being developed for the treatment of moderate to severe subtypes of CI. TMB-002, a topical rapamycin, is being developed for the treatment of facial angiofibromas (FAs) in TSC. TMB-003 is a topical / subcutaneous ET-A receptor antagonist, which is being developed for localized scleroderma.